Non-interventional Study With Pomalidomide (ImnovidÂ®)
The purpose of this non-interventional study is to collect data on the efficiency and safety of pomalidomide in combination with dexamethasone in the routine application
Multiple Myeloma
Progression free survival (PFS), 6 years
Overall Response Rate (ORR), 6 years|Time to Treatment Discontinuation (TTD), 6 years|Time to next treatment (TNT), 6 years|adverse reaction profile, 3 years|secondary malignancies, long term safety is focused on secondary malignancies, 6 years|overall Survival (OS), 6 years|relative dose intensity of pomalidomide and dexamethasone, 3 years|assess changes in myeloma-related quality of life, 3 years|explore additional supportive therapies, To explore additional supportive therapies used on this patient population (e.g. G-CSF, antibiotics, DVT prophylaxis), 3 years
The purpose of this non-interventional study is to collect data on the efficiency and safety of pomalidomide in combination with dexamethasone in the routine application